Silver Book Fact

It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%, in 2 years.  This means that 11,784 people would be spared blindness in that time period.

Bressler N, Doan Q, Varma R, Lee P, et al. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/427350

Reference

Title
Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration
Publication
Arch Ophthalmol
Publication Date
2011
Authors
Bressler N, Doan Q, Varma R, Lee P, et al
Volume & Issue
Volume 129, Issue 6
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • Mobile Exam for DR
    Use of a mobile examination for DR screening in Finland decreased visual impairment by 86% in the covered area.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy by 76% in type 1 diabetes patients who had not…